AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 616173446
Drug: Regular recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular recommended HF therapy (including maximized beta-blockade)
Trial: 35022014
Drug: Sertraline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (100 mg daily initially followed by 200 mg daily after week 4)
Trial: 33815503
Drug: One-session treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session treatment group with BioRoot RCS
Trial: 33815503
Drug: Two-session treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-session treatment group with BioRoot RCS
Trial: 34487844
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil (8 g daily for 12 weeks)
Trial: 34747917
Drug: Topical diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diltiazem (diltiazem group)
Trial: 34747917
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (placebo group)
Trial: 32197107
Drug: Two-dose primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose primary series (days 1 and 91)
Trial: 32197107
Drug: One primary
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One primary dose (day 1)
Trial: 32197107
Drug: One primary
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One primary dose plus booster (days 1 and 365)
Trial: 35545057
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin treatment for 6 weeks
Trial: 32706261
Drug: MitoQ (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitoQ (80 mg)
Trial: 35001842
Drug: No exercise/no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No exercise/no exposure therapy (control)
Trial: 34616808
Drug: Probiotics (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (2 g) added to a low FODMAP diet
Trial: 34737837
Drug: Bloodletting at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bloodletting at Shaoshang (LU11) and Shangyang (LI1) acupuncture points, 2-3 ml volume, repeated three times (once daily)
Trial: 34558993
Drug: Self-resisted neck
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-resisted neck strength training (3 times weekly for 8 weeks)
Trial: 33185628
Drug: Amifampridine (3,4-diaminopyridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifampridine (3,4-diaminopyridine [3,4-DAP]) at a recommended dose of 80 mg a day, divided 3 or 4 times a day.
Trial: 32203453
Drug: Luseogliflozin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin 2.5 mg daily (or up to 5 mg daily)
Trial: 33847047
Drug: ramipril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril (ACE inhibitor)
Trial: 32103567
Drug: Daily surveys
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily surveys assessing PTSD symptoms
Trial: 34074291
Drug: Percutaneous periarticular
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous periarticular injection including methylprednisolone, ropivacaine, and epinephrine at 1 day after surgery
Trial: 34074291
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional injection (control group)
Trial: 35772665
Drug: Placebo (platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (platinum-based chemotherapy)
Trial: 35772665
Drug: Olaparib (platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (platinum-based chemotherapy)
Trial: 35772665
Drug: Placebo (non-platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (non-platinum-based chemotherapy)
Trial: 35772665
Drug: Olaparib (non-platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (non-platinum-based chemotherapy)
Trial: 33774848
Drug: Metformin extended-release
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin extended-release 1500 mg daily for 26 weeks
Trial: 33501595
Drug: JWH‐018 (75μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JWH‐018 (75μg/kg bodyweight, average dose 5.52 mg)
Trial: 33877876
Drug: Empagliflozin as
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin as an add-on therapy
Trial: 33033962
Drug: Ivabradine co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine co-administered with ketoconazole (CYP3A4 inhibitor)
Trial: 35460449
Drug: Guided self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-help family-based treatment (GSH-FBT)
Trial: 35460449
Drug: Family-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based treatment delivered via videoconferencing (FBT-V)
Trial: 35274413
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta‐1a (sc IFN β‐1a) 44 μg once or three times weekly
Trial: 32024852
Drug: NaHCO3 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 (up to 100 mg·kg‐1)
Trial: 33576936
Drug: 165 μg
RxNorm normalized name: griseofulvin 165 MG [Fulvicin P/G]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 165 μg PEGylated exenatide
Trial: 33576936
Drug: 330 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 μg PEGylated exenatide
Trial: 33576936
Drug: 660 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 660 μg PEGylated exenatide
Trial: 35365535
Drug: Proactive TDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive TDM combined PK dashboard-driven infliximab dosing
Trial: 35365535
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) infliximab therapy
Trial: 32332458
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/d for 15 days)
Trial: 32332458
Drug: Memantine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (10 mg/d for 15 days)
Trial: 33152448
Drug: 18 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 doses of 40 mg/m2 of prednisone on alternate days (short arm)
Trial: 33152448
Drug: Cumulative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative dose of prednisone tapered over double the time (long arm)
Trial: 33152448
Drug: Post-hoc analysis
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-hoc analysis excluding 30 patients treated with low-dose prednisone maintenance therapy
Trial: 35622854
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (500,000 IU single oral dose)
Trial: 32187881
Drug: Licogliflozin 50
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin 50 mg twice daily
Trial: 32187881
Drug: Licogliflozin 150
RxNorm normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin 150 mg once daily
Trial: 34837648
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone (8 mg once daily)
Trial: 34837648
Drug: Intermediate-dose dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose dexamethasone (8 mg twice daily)
Trial: 34837648
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (8 mg thrice daily)
Trial: 34708640
Drug: Integrated Traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Traditional Chinese and Western Medicine
Trial: 34708640
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated according to Western Medicine guidelines
Trial: 32186587
Drug: High-Flow Nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Nasal Cannula (HFNC) Oxygen Therapy
Trial: 32639389
Drug: Low-dose dexmedetomidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexmedetomidine 0.2 μg·kg‐1 (group LD)
Trial: 32639389
Drug: High-dose dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexmedetomidine 0.5 μg·kg‐1 (group HD)
Trial: 32971163
Drug: Myrrh extract
RxNorm normalized name: myrrh extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myrrh extract sitz-bath (10-min, twice a day for 1 week)
Trial: 32971163
Drug: Frankincense extract
RxNorm normalized name: frankincense extract
DrugBank: Frankincense (DB16592)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frankincense extract sitz-bath (10-min, twice a day for 1 week)
Trial: 32971163
Drug: Betadine sitz-bath
RxNorm normalized name: SITZ BATH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betadine sitz-bath (10-min, twice a day for 1 week)
Trial: 35910688
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (CBT) intervention
Trial: 32113466
Drug: Simparica Trio™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simparica Trio™ (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)
Trial: 32113466
Drug: Sarolaner-alone (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarolaner-alone (1.2 mg/kg)
Trial: 32113466
Drug: Moxidectin-alone (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxidectin-alone (24 µg/kg)
Trial: 32113466
Drug: Pyrantel-alone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrantel-alone (5 mg/kg)
Trial: 36045484
Drug: LY06006 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY06006 (60 mg)
Trial: 34463234
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) and sertraline (SERT)
Trial: 34463234
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) and pill placebo
Trial: 35962142
Drug: Prolonged (week‐long)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged (week‐long) daily administration of the SSRI citalopram
Trial: 35962142
Drug: Acute (single‐dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute (single‐dose) administration of the SSRI citalopram
Trial: 35545584
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii combined with triple therapy for 14 days and triple therapy for 10 days
Trial: 35545584
Drug: Bismuth quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth quadruple therapy for 10 days
Trial: 32118723
Drug: LISA (less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LISA (less invasive surfactant administration via gastric tube)
Trial: 34551907
Drug: Hypomethylating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypomethylating agents (Azacitidine and Decitabine)
Trial: 34551907
Drug: Investigational agents
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational agents (less active)
Trial: 34551907
Drug: Cytostatic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytostatic agents
Trial: 34551907
Drug: Agents manipulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agents manipulating pyrimidine metabolism
Trial: 32585670
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (pooled treatment groups)
Trial: 32941737
Drug: Ketone monoester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone monoester (KME) supplement (0.45 mL/kg)
Trial: 32755265
Drug: Cognitive-narrative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-narrative therapy (4 sessions)
Trial: 32977253
Drug: AS1000 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS1000 group (L‐arginine, 1 g; folate, 200 μg)
Trial: 32977253
Drug: AS2000 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS2000 group (L‐arginine, 2 g; folate, 400 μg; vitamin E, 10 mg)
Trial: 32977253
Drug: Global L‐arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Global L‐arginine group (AS1000 and AS2000)
Trial: 32977253
Drug: L‐arginine groups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐arginine groups (AS1000 and AS2000) in male infertility subgroup
Trial: 35014217
Drug: GDC-0134 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0134 (up to 1200 mg daily)
Trial: 32456442
Drug: EPs 7630,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPs 7630, 3 × 20 mg/day for 10 days
Trial: 32456442
Drug: Amoxicillin, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, 3 × 500 mg/day for 10 days
Trial: 36602846
Drug: Relapse prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse prevention treatment
Trial: 32152813
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) 3.0 g via subfascial drain
Trial: 32152813
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 1.5 g just before wound closure
Trial: 32152813
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and IV TXA
Trial: 32000724
Drug: HAI oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HAI oxaliplatin plus systemic FOLFIRI plus targeted therapy (anti-EGFR antibody or bevacizumab)
Trial: 32000724
Drug: Conventional systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional systemic chemotherapy (sys-CT) plus targeted therapy (anti-EGFR or antiangiogenic antibody)
Trial: 35409483
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support plus daily text messages
Trial: 35409483
Drug: Daily supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supportive text messages only
Trial: 33412465
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg twice daily and pembrolizumab 2 mg/kg every 3 weeks
Trial: 35509077
Drug: NTHi-Mcat vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTHi-Mcat vaccine (0-2-6 months)
Trial: 35509077
Drug: NTHi-Mcat vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTHi-Mcat vaccine (0-2-12 months)
Trial: 35509077
Drug: NTHi-Mcat vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTHi-Mcat vaccine (both schedules)
Trial: 34262664
Drug: Developmentally adapted
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developmentally adapted cognitive processing therapy (D-CPT)
Trial: 36641898
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lapatinib and trastuzumab
Trial: 32869586
Drug: Interaction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interaction of twelve meridian muscle regions and contralateral needling therapy
Trial: 32869586
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of mecobalamine and oral citicoline sodium capsules
Trial: 32366139
Drug: Industrial beer
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Industrial beer (4.5% alcohol), 330 ml daily for 3 weeks
Trial: 32366139
Drug: Craft beer
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craft beer (9% alcohol), 330 ml daily for 3 weeks
Trial: 35915802
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition support on a routine basis
Trial: 32716291
Drug: Rizatriptan oral
RxNorm normalized name: rizatriptan Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan oral gel (test)
Trial: 32716291
Drug: Rizatriptan oral
RxNorm normalized name: rizatriptan Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan oral lyophilisate (reference)
Trial: 33728385
Drug: Aayudh Advance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aayudh Advance (herbal formulation)
Trial: 33728385
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care treatment
Trial: 36056399
Drug: Robotic walking
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic walking rehabilitation treatment (experimental group)
Trial: 36056399
Drug: Conventional gait
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional gait rehabilitation treatment (control group)
Trial: 35810173
Drug: Gratitude expression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gratitude expression treatment (GET)
Trial: 33221898
Drug: Antimicrobial prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial prescriptions during inpatient admissions
Trial: 33221898
Drug: Antimicrobial prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial prescriptions in neonatal sepsis
Trial: 33221898
Drug: Antimicrobial prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial prescriptions in lower respiratory tract infection (LRTI)
Trial: 33221898
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of antimicrobial prescription rates
Trial: 34417443
Drug: Testosterone (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (0.50 mg)
Trial: 32049889
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin at 8:00 hours
Trial: 32049889
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin at 22:00 hours
Trial: 33600729
Drug: Short-acting bronchodilators
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting bronchodilators
Trial: 37936408
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (ICS) therapy
Trial: 33561426
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone 4 mg administered preemptively
Trial: 34786952
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency treatment (PRF) with pregabalin
Trial: 34399547
Drug: L-cysteine hydrochloride;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-cysteine hydrochloride; concentration 4.23 mM at pH 8.71
Trial: 35686393
Drug: Technology-enhanced physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology-enhanced physical activity intervention (bi-weekly education sessions for 4 weeks, monthly small group walks for 8 weeks, weekly reminder text messages)
Trial: 32921337
Drug: Lurasidone (40‐160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (40‐160 mg/d)
Trial: 36261491
Drug: Gel group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel group (poloxamer 407‐based 0.75% ropivacaine, 22.5 mg)
Trial: 36261491
Drug: On-Q group
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-Q group (0.2% ropivacaine, 4 mg/hour for two days)
Trial: 36261491
Drug: Gel group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel group
Trial: 35927674
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of 10^7 umbilical cord-derived Wharton's jelly mesenchymal stem cells (WJ-MSCs)
Trial: 35582785
Drug: Dextromethorphan-bupropion (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan-bupropion (45 mg/105 mg tablet)
Trial: 35582785
Drug: Bupropion (105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (105 mg tablet)
Trial: 33864432
Drug: Standard tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard tuberculosis therapy alone
Trial: 37165291
Drug: Rasburicase 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasburicase 0.20 mg/kg/day